Revive Therapeutics (RVV.C) entered into a memorandum of understanding with Indian pharmaceutical company, Supriya Lifescience, which includes manufacturing, clinical registration and commercialization for Bucillamine, according to a press release.

 

The company has been busy for the past year performing tests and doing general preparation work with Bucillamine, a drug commonly used in treating rheumatoid arthritis, for repurposing in the fight against COVID-19. This relationship will give the company another angle by which to approach their testing, while also setting the foundation for Revive to expand their commercialization efforts globally by using Supriya’s considerable manufacturing and commercial network.

 

“While our Phase 3 clinical study for COVID-19 is ongoing in the USA, we  are laying the ground work by partnering with Supriya to execute on our global manufacturing and commercialization plans and leveraging their regulatory expertise and commercial reach with 78 countries they currently supply pharmaceutical products to. We are focused on completing our current Phase 3 study in the USA and also obtaining EUA. These results will support drug approval registrations globally, including India, Europe, and Canada,” said Michael Frank, CEO of Revive.

What is Supriya Lifescience?

Supriya is a Mumbai, India based European manufacturer and supplier of active ingredients for pharmaceutical companies and products. They export ot 78 countries and have niche product offerings of applied pharmaceutical innovations (API) including such options like antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.

 

“Through this collaboration, we aim to join our forces with Revive  to accelerate access to Bucillamine in India at a time when it is most needed. This is a step towards making more treatment options available to patients in India in dealing with the pandemic. With this partnership, Supriya aims to enter into a niche area of chemistry and products thereby bolstering its CMO and research capabilities,” said Dr. Satish Wagh, CMD, Supriya Lifescience.

 

Source: stockwatch.com

—Joseph Morton

Full disclosure: Revive Therapeutics is an equity guru marketing client.

Written By:

Joseph Morton

Joseph is a Vancouver-based author and journalist with both a communications degree and journalism diploma (and a few novels) under his belt. His joie de vivre is to spin difficult technical topics into more human-centric narratives. Buy him a coffee and he'll talk your ear off for hours about privacy issues, blockchain, cryptocurrency and martial arts. Don't talk to him if you're either a tomato, a bully, or if you're not a fan of either 1984 or Tender is the Night. No. You can still talk to him. Just be prepared to be told why you're wrong.

More By This Author
Tags:
Health Science
Pharmaceuticals
Bucillamine
COVID-19
Covid-19 treatment
end the pandemic
Indian based pharmaceutical companies
memorandum of understanding
pandemic
Revive Therapeutics
RVV.C
Supriya LIfescience
5 1 vote
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x